The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2022 | Using AI to predict the outcomes of patients with R/R DLBCL treated with tisagenlecleucel
Margot Jak, MD, University Medical Center Utrecht, Utrecht, the Netherlands, discusses a study which used an artificial intelligence (AI) model to predict the outcomes of patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL) treated with tisagenlecleucel (tisa-cel) in the JULIET trial (NCT02445248). Patients with negative AI signatures almost universally showed poorer outcomes, indicating that this prediction model may be a valuable tool. This interview took place at the 64th ASH Annual Meeting and Exposition congress held in New Orleans, LA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
